Clarity Can Continue to Tap Interesting Potential in Image Testing, Says Jefferies

MT Newswires Live

Dec 17, 2025

Clarity Pharmaceuticals (ASX:CU6) can continue to unlock potential from NET diagnostics amid promising results from its specialized imaging testing trial for neuroendocrine tumors, Jefferies said in a note on Tuesday.

The phase two trial for its radiopharmaceutical tracer, 64Cu-Sartate, identified more lesions than the competition.

The brokerage expects to see its additional phase three trial for prostate cancer diagnostics, set to conclude this month, to be in line or better in terms of sensitivity.

Jefferies upgraded the stock to buy from hold, banking on its share performance, and maintained the price target at A$5.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2592895521"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592895521\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592895521?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 07:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592895521","market":"sg","top_or_hot":-1,"title":"Clarity Can Continue to Tap Interesting Potential in Image Testing, Says Jefferies","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> (ASX:CU6) can continue to unlock potential from NET diagnostics amid promising results from its specialized imaging testing trial for neuroendocrine tumors, Jefferies said in a note on Tuesday.</p><p>The phase two trial for its radiopharmaceutical tracer, 64Cu-Sartate, identified more lesions than the competition.</p><p>The brokerage expects to see its additional phase three trial for prostate cancer diagnostics, set to conclude this month, to be in line or better in terms of sensitivity.</p><p>Jefferies upgraded the stock to buy from hold, banking on its share performance, and maintained the price target at A$5.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clarity Can Continue to Tap Interesting Potential in Image Testing, Says Jefferies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClarity Can Continue to Tap Interesting Potential in Image Testing, Says Jefferies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-17 07:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> (ASX:CU6) can continue to unlock potential from NET diagnostics amid promising results from its specialized imaging testing trial for neuroendocrine tumors, Jefferies said in a note on Tuesday.</p><p>The phase two trial for its radiopharmaceutical tracer, 64Cu-Sartate, identified more lesions than the competition.</p><p>The brokerage expects to see its additional phase three trial for prostate cancer diagnostics, set to conclude this month, to be in line or better in terms of sensitivity.</p><p>Jefferies upgraded the stock to buy from hold, banking on its share performance, and maintained the price target at A$5.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592895521","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592895521","pubTimestamp":1765929250,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clarity Pharmaceuticals (ASX:CU6) can continue to unlock potential from NET diagnostics amid promising results from its specialized imaging testing trial for neuroendocrine tumors, Jefferies said in a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","CU6.AU":"CLARITY PHARMACEUTICALS LTD"},"translate_title":"Jefferies表示，Clarity可以继续挖掘图像测试的有趣潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CU6.AU":1},"content_text":"Clarity Pharmaceuticals (ASX:CU6) can continue to unlock potential from NET diagnostics amid promising results from its specialized imaging testing trial for neuroendocrine tumors, Jefferies said in a note on Tuesday.The phase two trial for its radiopharmaceutical tracer, 64Cu-Sartate, identified more lesions than the competition.The brokerage expects to see its additional phase three trial for prostate cancer diagnostics, set to conclude this month, to be in line or better in terms of sensitivity.Jefferies upgraded the stock to buy from hold, banking on its share performance, and maintained the price target at A$5.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}